Mochida Pharmaceutical has announced the launch of the first biosimilar in Japan of Eli Lilly’s blockbuster osteoporosis drug Forteo (teriparatide). The company hopes to clock significant sales from the biosimilar in Japan, where life expectancy is among the longest in the world and rates of osteoporosis are increasing.
The Mochida product is also the first biosimilar to go on sale in Japan’s osteoporosis market. Mochida said it developed...






